ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VRCA vs MRK // GROSS PROFIT MARGIN

Verrica Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: VRCA 1 — MRK 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRCA VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VRCA MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 74.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 20.70% -55.70 MRK /roic <GO>
EV/EBITDA & P/E Valuation — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield — 3.42% — TIE /fcf-yield <GO>
Operating Margin -34.20% 34.30% -68.50 MRK /operating-margins <GO>
Net Profit Margin -50.30% 28.10% -78.40 MRK /net-margins <GO>
Revenue Growth (YoY) 180.00% 1.30% +178.70 VRCA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 7/9 -3.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 34.1 51.7 -17.60 MRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $58.8M $361.02B -$360.96B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VRCA REV MRK REV VRCA GROSS % MRK GROSS % VRCA FCF MRK FCF
FY 2025 $35.6M $65.01B — 74.8% -$17.6M $12.36B
FY 2024 $7.6M $64.17B 65.6% 76.3% -$61.0M $18.10B
FY 2023 $5.1M $60.12B — — -$38.6M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRCA // BETA —
MRK // BETA 0.92